Alzheimer's disease literature — master bibliography

Last updated: 2026-09-03 (evidence-breadth deepening)

Every PMID used anywhere in this condition appears once below. All records were resolved through live PubMed E-utilities during the 2026-08-31 build, and the citation metadata in this file was regenerated from those live records rather than transcribed. Entries are grouped by the record's first major domain in this knowledge base; cited by preserves every file that uses it.

Records: 373.

Definition, diagnostic criteria and staging

• Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011. PMID 21514249 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, wiki/clinical-presentation-and-staging.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md
• Bader I, et al. Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease. Neurology. 2025. PMID 40294367 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md
• Chapleau M, et al. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet Neurol. 2024. PMID 38267189 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md
• Clark LR, et al. Psychosocial implications of learning amyloid PET results in an observational cohort. Alzheimers Dement. 2024. PMID 39129396 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: OPEN-QUESTIONS.md, wiki/diagnostic-criteria-and-biological-definition.md
• Crutch SJ, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017. PMID 28259709 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Dubois B, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014. PMID 24849862 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md
• Dubois B, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. JAMA Neurol. 2024. PMID 39483064 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/jack-2024-revised-criteria.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md, wiki/overview.md
• Folstein MF, et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975. PMID 1202204 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011. PMID 21325651 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Graff-Radford J, et al. New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol. 2021. PMID 33609479 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Grill JD, et al. Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurol Clin Pract. 2024. PMID 38585443 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: OPEN-QUESTIONS.md, wiki/diagnostic-criteria-and-biological-definition.md
• Iacono D, et al. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology. 2009. PMID 19587326 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/diagnostic-criteria-and-biological-definition.md
• Jack CR, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011. PMID 21514247 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md
• Jack CR, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018. PMID 29653606 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: INDEX.md, literature/guidelines/REGISTRY.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md, wiki/overview.md
• Jack CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024. PMID 38934362 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/jack-2024-revised-criteria.md, literature/patient-voice/organizations.md, wiki/clinical-presentation-and-staging.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/fluid-biomarkers.md, wiki/guidelines.md, wiki/overview.md
• Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015. PMID 25988462 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/amyloid-biology.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/genetics.md, wiki/overview.md
• Kern S, et al. Prevalence of preclinical Alzheimer disease: Comparison of current classification systems. Neurology. 2018. PMID 29653987 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, literature/notes/jack-2024-revised-criteria.md, literature/statistics/STATISTICS.md, wiki/diagnostic-criteria-and-biological-definition.md
• Liang CS, et al. Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2021. PMID 36097997 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md, wiki/epidemiology-and-burden.md, wiki/overview.md
• McKhann G, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984. PMID 6610841 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md
• McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011. PMID 21514250 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, wiki/clinical-presentation-and-staging.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md
• Mitchell AJ, et al. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009. PMID 19236314 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md
• Mitchell SL, et al. The clinical course of advanced dementia. N Engl J Med. 2009. PMID 19828530 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/clinical-presentation-and-staging.md
• Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997. PMID 9447441 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Moscoso A, et al. Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity. JAMA. 2025. PMID 40522652 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: OPEN-QUESTIONS.md, literature/notes/jack-2024-revised-criteria.md, literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/imaging-and-neuropathology.md, wiki/overview.md, wiki/tau-biology-and-spread.md
• Muir RT, et al. Minimal clinically important difference in Alzheimer's disease: Rapid review. Alzheimers Dement. 2024. PMID 38561021 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/sims-2023-trailblazer-alz2.md, literature/notes/vandyck-2023-clarity-ad.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-presentation-and-staging.md, wiki/overview.md, wiki/symptomatic-and-supportive-therapy.md
• Murray ME, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011. PMID 21802369 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md, wiki/tau-biology-and-spread.md
• Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005. PMID 15817019 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Ossenkoppele R, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain. 2015. PMID 26141491 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Parnetti L, et al. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. Alzheimers Res Ther. 2019. PMID 30646955 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/diagnostic-criteria-and-biological-definition.md
• Reisberg B, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982. PMID 7114305 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988. PMID 3249767 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Santos-Santos MA, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018. PMID 29309493 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Schneider JA, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007. PMID 17568013 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/boyle-2018-person-specific-pathologies.md, literature/statistics/STATISTICS.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/epidemiology-and-burden.md, wiki/overview.md, wiki/vascular-and-metabolic-contributions.md
• Sclan SG, et al. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992. PMID 1504288 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/clinical-presentation-and-staging.md
• Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011. PMID 21514248 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/guidelines/REGISTRY.md, wiki/clinical-presentation-and-staging.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/guidelines.md
• Tschanz JT, et al. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry. 2011. PMID 21606896 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md
• Vermunt L, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019. PMID 31164314 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md
• Vos SJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013. PMID 24012374 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: OPEN-QUESTIONS.md, literature/notes/jack-2024-revised-criteria.md, literature/statistics/STATISTICS.md, wiki/clinical-presentation-and-staging.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/overview.md
• Jack CR, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010. PMID 20083042 — tags: [alzheimers-disease, definition-criteria-staging] — cited by: wiki/diagnostic-criteria-and-biological-definition.md

Epidemiology, burden and cost

• . 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024. PMID 38689398 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/patient-voice/organizations.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Corrada MM, et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010. PMID 20186856 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Fang M, et al. Lifetime risk and projected burden of dementia. Nat Med. 2025. PMID 39806070 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md, wiki/overview.md
• Farina N, et al. Comprehensive measurement of the prevalence of dementia in low- and middle-income countries: STRiDE methodology and its application in Indonesia and South Africa. BJPsych Open. 2023. PMID 37278200 — tags: [alzheimers-disease, epidemiology-burden] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. PMID 30497964 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md, wiki/risk-reduction-and-prevention.md
• GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022. PMID 34998485 — tags: [alzheimers-disease, epidemiology-burden] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/patient-voice/README.md, literature/patient-voice/sources.md, literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md, wiki/overview.md, wiki/risk-reduction-and-prevention.md
• GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024. PMID 38493795 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Gilsanz P, et al. Incidence of dementia after age 90 in a multiracial cohort. Alzheimers Dement. 2019. PMID 30797730 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Gross AL, et al. Prevalence of DSM-5 mild and major neurocognitive disorder in India: Results from the LASI-DAD. PLoS One. 2024. PMID 38324518 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/patient-voice/organizations.md, literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Hendriks S, et al. Global incidence of young-onset dementia: A systematic review and meta-analysis. Alzheimers Dement. 2023. PMID 35715891 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Hendriks S, et al. Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurol. 2021. PMID 34279544 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Lastuka A, et al. Societal Costs of Dementia: 204 Countries, 2000-2019. J Alzheimers Dis. 2024. PMID 39150827 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Lin PJ, et al. Dementia Diagnosis Disparities by Race and Ethnicity. Med Care. 2021. PMID 34091580 — tags: [alzheimers-disease, epidemiology-burden] — cited by: OPEN-QUESTIONS.md, literature/notes/palmqvist-2024-blood-biomarkers-primary-care.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Manly JJ, et al. Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. JAMA Neurol. 2022. PMID 36279130 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md, wiki/overview.md
• Matthews KA, et al. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement. 2019. PMID 30243772 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Mayeda ER, et al. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016. PMID 26874595 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Ohara T, et al. Thirty-seven-year trends in the prevalence, incidence, and prognosis of dementia in a Japanese community: the Hisayama study. Alzheimers Res Ther. 2025. PMID 41466306 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Ohara T, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology. 2017. PMID 28424272 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Reeves D, et al. Retrospective study of more than 5 million emergency admissions to hospitals in England: Epidemiology and outcomes for people with dementia. PLoS One. 2023. PMID 36888666 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Roehr S, et al. Is dementia incidence declining in high-income countries? A systematic review and meta-analysis. Clin Epidemiol. 2018. PMID 30271219 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md
• Skoog I, et al. Decreasing prevalence of dementia in 85-year olds examined 22 years apart: the influence of education and stroke. Sci Rep. 2017. PMID 28733627 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md, wiki/risk-reduction-and-prevention.md, wiki/vascular-and-metabolic-contributions.md
• Toot S, et al. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr. 2017. PMID 27806743 — tags: [alzheimers-disease, epidemiology-burden] — cited by: wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Wimo A, et al. The worldwide costs of dementia in 2019. Alzheimers Dement. 2023. PMID 36617519 — tags: [alzheimers-disease, epidemiology-burden] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md, wiki/overview.md
• Wolters FJ, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: The Alzheimer Cohorts Consortium. Neurology. 2020. PMID 32611641 — tags: [alzheimers-disease, epidemiology-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-burden.md, wiki/risk-reduction-and-prevention.md
• Satizabal CL, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016. PMID 26863354 — tags: [alzheimers-disease, epidemiology-burden] — cited by: wiki/epidemiology-and-burden.md, wiki/risk-reduction-and-prevention.md

Genetics

• Arboleda-Velasquez JF, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019. PMID 31686034 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012. PMID 22784036 — tags: [alzheimers-disease, genetics] — cited by: wiki/amyloid-biology.md, wiki/clinical-trials-landscape.md, wiki/fluid-biomarkers.md, wiki/genetics.md
• Bellenguez C, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022. PMID 35379992 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md, wiki/neuroinflammation-and-glia.md
• Belloy ME, et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurol. 2023. PMID 37930705 — tags: [alzheimers-disease, genetics] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/genetics.md
• Chao S, et al. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord. 2008. PMID 18317253 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Christensen KD, et al. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med. 2016. PMID 26810768 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• EADB, et al. Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias. Nat Genet. 2026. PMID 42237039 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997. PMID 9343467 — tags: [alzheimers-disease, genetics] — cited by: literature/statistics/STATISTICS.md, wiki/genetics.md
• Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nat Med. 2024. PMID 38710950 — tags: [alzheimers-disease, genetics] — cited by: OPEN-QUESTIONS.md, wiki/amyloid-biology.md, wiki/anti-amyloid-immunotherapy.md, wiki/genetics.md
• Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006. PMID 16461860 — tags: [alzheimers-disease, genetics] — cited by: literature/statistics/STATISTICS.md, wiki/genetics.md
• Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013. PMID 23150934 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md, wiki/neuroinflammation-and-glia.md
• Holstege H, et al. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. Nat Genet. 2022. PMID 36411364 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Iulita MF, et al. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Netw Open. 2022. PMID 35604690 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013. PMID 23150908 — tags: [alzheimers-disease, genetics] — cited by: literature/statistics/STATISTICS.md, wiki/genetics.md, wiki/neuroinflammation-and-glia.md, wiki/overview.md
• Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019. PMID 30820047 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md, wiki/neuroinflammation-and-glia.md
• Kunkle BW, et al. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol. 2021. PMID 33074286 — tags: [alzheimers-disease, genetics] — cited by: OPEN-QUESTIONS.md, wiki/genetics.md
• Lanoiselée HM, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017. PMID 28350801 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• LaRusse S, et al. Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med. 2005. PMID 15654228 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Liu H, et al. The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset. Brain. 2025. PMID 39903689 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Rafii MS, et al. Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology. Lancet Neurol. 2025. PMID 40818475 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md
• Reitz C, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013. PMID 23571587 — tags: [alzheimers-disease, genetics] — cited by: literature/statistics/STATISTICS.md, wiki/genetics.md
• Roberts JS, et al. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005. PMID 16306249 — tags: [alzheimers-disease, genetics] — cited by: wiki/genetics.md

Amyloid biology

• Boon BDC, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025. PMID 41109234 — tags: [alzheimers-disease, amyloid-biology] — cited by: OPEN-QUESTIONS.md, wiki/amyloid-biology.md, wiki/anti-amyloid-immunotherapy.md, wiki/imaging-and-neuropathology.md, wiki/red-flags-and-safety-concerns.md, wiki/vascular-and-metabolic-contributions.md
• Doody RS, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013. PMID 23883379 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/clinical-trials-landscape.md
• Hardy J, et al. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002. PMID 12130773 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Hardy JA, et al. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992. PMID 1566067 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015. PMID 26007212 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Holmes C, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008. PMID 18640458 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/clinical-trials-landscape.md
• Jonsson T, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012. PMID 22801501 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/overview.md
• Karran E, et al. The amyloid cascade hypothesis: are we poised for success or failure?. J Neurochem. 2016. PMID 27255958 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Li X, et al. Seeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer's disease. Brain. 2022. PMID 36270003 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/tau-biology-and-spread.md
• Mawuenyega KG, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010. PMID 21148344 — tags: [alzheimers-disease, amyloid-biology] — cited by: OPEN-QUESTIONS.md, wiki/amyloid-biology.md, wiki/overview.md
• Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012. PMID 22487856 — tags: [alzheimers-disease, amyloid-biology] — cited by: literature/notes/braak-1991-staging.md, wiki/amyloid-biology.md, wiki/imaging-and-neuropathology.md, wiki/overview.md, wiki/tau-biology-and-spread.md
• Selkoe DJ, et al. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016. PMID 27025652 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/overview.md
• Shokri-Kojori E, et al. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A. 2018. PMID 29632177 — tags: [alzheimers-disease, amyloid-biology] — cited by: OPEN-QUESTIONS.md, wiki/amyloid-biology.md
• Thal DR, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002. PMID 12084879 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/imaging-and-neuropathology.md, wiki/tau-biology-and-spread.md
• Wessels AM, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimers Dement. 2020. PMID 33049114 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/clinical-trials-landscape.md
• Glenner GG, et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984. PMID 6375662 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Goate A, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991. PMID 1671712 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Sherrington R, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995. PMID 7596406 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002. PMID 11932745 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md
• Egan MF, et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018. PMID 29719179 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/clinical-trials-landscape.md
• Egan MF, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019. PMID 30970186 — tags: [alzheimers-disease, amyloid-biology] — cited by: wiki/amyloid-biology.md, wiki/clinical-trials-landscape.md

Tau biology and spread

• Braak H, et al. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991. PMID 1759558 — tags: [alzheimers-disease, tau-biology] — cited by: OPEN-QUESTIONS.md, literature/notes/braak-1991-staging.md, wiki/imaging-and-neuropathology.md, wiki/tau-biology-and-spread.md
• Cai W, et al. Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials. Front Aging Neurosci. 2024. PMID 39945003 — tags: [alzheimers-disease, tau-biology] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md, wiki/tau-biology-and-spread.md
• Edwards AL, et al. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID 37902726 — tags: [alzheimers-disease, tau-biology] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md, wiki/tau-biology-and-spread.md
• Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017. PMID 28678775 — tags: [alzheimers-disease, tau-biology] — cited by: OPEN-QUESTIONS.md, wiki/tau-biology-and-spread.md
• Franzmeier N, et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. Sci Adv. 2020. PMID 33246962 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/tau-biology-and-spread.md
• La Joie R, et al. Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020. PMID 31894103 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/imaging-and-neuropathology.md, wiki/overview.md, wiki/tau-biology-and-spread.md
• Ossenkoppele R, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016. PMID 26962052 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/imaging-and-neuropathology.md, wiki/tau-biology-and-spread.md
• Richardson TE, et al. Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration. Acta Neuropathol. 2026. PMID 42184025 — tags: [alzheimers-disease, tau-biology] — cited by: OPEN-QUESTIONS.md, literature/notes/braak-1991-staging.md, literature/statistics/STATISTICS.md, wiki/tau-biology-and-spread.md, wiki/vascular-and-metabolic-contributions.md
• Steward A, et al. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels. JAMA Neurol. 2023. PMID 37930695 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/tau-biology-and-spread.md
• Strang KH, et al. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019. PMID 30742061 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/tau-biology-and-spread.md
• Vogel JW, et al. Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med. 2021. PMID 33927414 — tags: [alzheimers-disease, tau-biology] — cited by: OPEN-QUESTIONS.md, literature/notes/braak-1991-staging.md, wiki/tau-biology-and-spread.md
• Hutton M, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998. PMID 9641683 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/tau-biology-and-spread.md
• Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023. PMID 38012285 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/clinical-trials-landscape.md, wiki/tau-biology-and-spread.md
• Teng E, et al. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID 35696185 — tags: [alzheimers-disease, tau-biology] — cited by: wiki/clinical-trials-landscape.md, wiki/tau-biology-and-spread.md

Neuroinflammation and glia

• ADAPT Research Group, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008. PMID 18474729 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013. PMID 23562431 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: literature/statistics/STATISTICS.md, wiki/neuroinflammation-and-glia.md
• Hamelin L, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. Brain. 2018. PMID 29608645 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: OPEN-QUESTIONS.md, wiki/neuroinflammation-and-glia.md, wiki/overview.md
• Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016. PMID 27033548 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017. PMID 28099414 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Malpetti M, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. Brain. 2020. PMID 32380523 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Mathys H, et al. Single-cell multiregion dissection of Alzheimer's disease. Nature. 2024. PMID 39048816 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019. PMID 31042697 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Pelkmans W, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression. Alzheimers Dement. 2024. PMID 37690071 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/fluid-biomarkers.md, wiki/neuroinflammation-and-glia.md
• Stephenson HG, et al. Higher CSF sTREM2 is related to slower hippocampal atrophy and cognitive decline independently of pTau181 levels. Brain Behav Immun. 2026. PMID 41605308 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: OPEN-QUESTIONS.md, wiki/neuroinflammation-and-glia.md
• Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med. 2020. PMID 31932797 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: OPEN-QUESTIONS.md, wiki/neuroinflammation-and-glia.md
• Heneka MT, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013. PMID 23254930 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Ewers M, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med. 2019. PMID 31462511 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/neuroinflammation-and-glia.md
• Mummery CJ, et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nat Med. 2026. PMID 41787076 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/clinical-trials-landscape.md, wiki/neuroinflammation-and-glia.md, wiki/overview.md
• Howard R, et al. Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID 31738372 — tags: [alzheimers-disease, neuroinflammation-glia] — cited by: wiki/clinical-trials-landscape.md, wiki/neuroinflammation-and-glia.md

Vascular, metabolic and mixed pathology

• Arvanitakis Z, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004. PMID 15148141 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: literature/statistics/STATISTICS.md, wiki/vascular-and-metabolic-contributions.md
• Boyle PA, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018. PMID 29244218 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/boyle-2018-person-specific-pathologies.md, literature/notes/vandyck-2023-clarity-ad.md, literature/statistics/STATISTICS.md, wiki/overview.md, wiki/vascular-and-metabolic-contributions.md
• Charidimou A, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022. PMID 35841910 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: OPEN-QUESTIONS.md, wiki/vascular-and-metabolic-contributions.md
• Craft S, et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID 32568367 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/clinical-trials-landscape.md, wiki/vascular-and-metabolic-contributions.md
• Gottesman RF, et al. Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. JAMA. 2017. PMID 28399252 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/risk-reduction-and-prevention.md, wiki/vascular-and-metabolic-contributions.md
• Hampel H, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023. PMID 37280110 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/anti-amyloid-immunotherapy.md, wiki/red-flags-and-safety-concerns.md, wiki/vascular-and-metabolic-contributions.md
• Kapasi A, et al. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017. PMID 28488154 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/vascular-and-metabolic-contributions.md
• Kuźma E, et al. Stroke and dementia risk: A systematic review and meta-analysis. Alzheimers Dement. 2018. PMID 30177276 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: literature/statistics/STATISTICS.md, wiki/risk-reduction-and-prevention.md, wiki/vascular-and-metabolic-contributions.md
• Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020. PMID 32376954 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: OPEN-QUESTIONS.md, wiki/vascular-and-metabolic-contributions.md
• Nasrallah IM, et al. Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA Neurol. 2021. PMID 33683313 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/vascular-and-metabolic-contributions.md
• Nation DA, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019. PMID 30643288 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: OPEN-QUESTIONS.md, wiki/vascular-and-metabolic-contributions.md
• Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019. PMID 31039256 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/imaging-and-neuropathology.md, wiki/vascular-and-metabolic-contributions.md
• Shirzadi Z, et al. Vascular contributions to cognitive decline: Beyond amyloid and tau in the Harvard Aging Brain Study. J Cereb Blood Flow Metab. 2024. PMID 38452039 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/vascular-and-metabolic-contributions.md
• Edison P, et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nat Med. 2026. PMID 41326666 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/clinical-trials-landscape.md, wiki/vascular-and-metabolic-contributions.md
• Whitmer RA, et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005. PMID 15863436 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: wiki/risk-reduction-and-prevention.md, wiki/vascular-and-metabolic-contributions.md
• SPRINT MIND Investigators for the SPRINT Research Group, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019. PMID 30688979 — tags: [alzheimers-disease, vascular-metabolic-mixed-pathology] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/risk-reduction-and-prevention.md, wiki/vascular-and-metabolic-contributions.md

Fluid biomarkers

• Amft M, et al. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimers Res Ther. 2022. PMID 35473631 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md
• Arslan B, et al. The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity. Alzheimers Res Ther. 2025. PMID 39972340 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Hansson O, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022. PMID 35908251 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, wiki/fluid-biomarkers.md, wiki/guidelines.md
• Howe MD, et al. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease. Alzheimers Res Ther. 2024. PMID 38971815 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Jung Y, et al. The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain. 2024. PMID 37540027 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Kjaergaard D, et al. Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study. Alzheimers Dement. 2025. PMID 40501109 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Palmqvist S, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024. PMID 39068545 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/palmqvist-2024-blood-biomarkers-primary-care.md, literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md, wiki/guidelines.md, wiki/overview.md
• Palmqvist S, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020. PMID 32722745 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Schöll M, et al. Challenges in the practical implementation of blood biomarkers for Alzheimer's disease. Lancet Healthy Longev. 2024. PMID 39369727 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Therriault J, et al. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2025. PMID 40818474 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/jack-2024-revised-criteria.md, literature/notes/palmqvist-2024-blood-biomarkers-primary-care.md, literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md, wiki/overview.md
• Wang J, et al. Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts. Alzheimers Dement. 2025. PMID 40156286 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md
• Warmenhoven N, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. 2025. PMID 39468767 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: OPEN-QUESTIONS.md, literature/notes/palmqvist-2024-blood-biomarkers-primary-care.md, literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md
• Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016. PMID 27068280 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020. PMID 32333900 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Brum WS, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023. PMID 37653254 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md
• Barthélemy NR, et al. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024. PMID 38382645 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md, wiki/imaging-and-neuropathology.md
• Salvadó G, et al. Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease. JAMA Neurol. 2026. PMID 42189519 — tags: [alzheimers-disease, fluid-biomarkers] — cited by: wiki/fluid-biomarkers.md, wiki/imaging-and-neuropathology.md

Imaging and neuropathology

• Bakkour A, et al. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009. PMID 19109536 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: literature/statistics/STATISTICS.md, wiki/imaging-and-neuropathology.md
• Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011. PMID 21245183 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: literature/statistics/STATISTICS.md, wiki/imaging-and-neuropathology.md
• Fleisher AS, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020. PMID 32338734 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: OPEN-QUESTIONS.md, literature/notes/braak-1991-staging.md, literature/statistics/STATISTICS.md, wiki/imaging-and-neuropathology.md
• Hyman BT, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012. PMID 22265587 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: literature/guidelines/REGISTRY.md, wiki/imaging-and-neuropathology.md
• Johnson KA, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013. PMID 23359661 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/imaging-and-neuropathology.md
• Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004. PMID 14991808 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: wiki/imaging-and-neuropathology.md
• Klunk WE, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015. PMID 25443857 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: OPEN-QUESTIONS.md, wiki/imaging-and-neuropathology.md
• Montine TJ, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012. PMID 22101365 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/braak-1991-staging.md, wiki/imaging-and-neuropathology.md
• Rabinovici GD, et al. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA Neurol. 2023. PMID 37812437 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: wiki/imaging-and-neuropathology.md
• Rabinovici GD, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019. PMID 30938796 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: wiki/imaging-and-neuropathology.md
• Rabinovici GD, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025. PMID 39776249 — tags: [alzheimers-disease, imaging-neuropathology] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/patient-voice/organizations.md, wiki/guidelines.md, wiki/imaging-and-neuropathology.md

Anti-amyloid immunotherapy and the trial landscape

• Baker LD, et al. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA. 2025. PMID 40720610 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/risk-reduction-and-prevention.md
• Bateman RJ, et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023. PMID 37966285 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-trials-landscape.md
• Budd Haeberlein S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022. PMID 35542991 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-trials-landscape.md
• Honig LS, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018. PMID 29365294 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: wiki/anti-amyloid-immunotherapy.md
• Mintun MA, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021. PMID 33720637 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: wiki/anti-amyloid-immunotherapy.md
• Cummings J, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023. PMID 37357276 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, wiki/anti-amyloid-immunotherapy.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Cummings JL, et al. Alzheimer's disease drug development pipeline: 2025. Alzheimers Dement (N Y). 2025. PMID 40463637 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md
• Cummings JL, et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Res Ther. 2025. PMID 39780249 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md
• Cummings JL, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026. PMID 41865758 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md
• Cummings JL, et al. Globalization of Alzheimer's disease clinical trials: Current characteristics and future goals. Int Psychogeriatr. 2025. PMID 40555627 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md, wiki/risk-reduction-and-prevention.md
• Heneka MT, et al. Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challenges. Lancet. 2024. PMID 39549715 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: wiki/anti-amyloid-immunotherapy.md, wiki/care-caregiving-and-health-systems.md
• Hoang MT, et al. Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis. Alzheimers Dement. 2026. PMID 42125995 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/care-caregiving-and-health-systems.md
• Jeon SY, et al. Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations. Alzheimers Dement. 2025. PMID 41225766 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/care-caregiving-and-health-systems.md, wiki/guidelines.md
• Lee D, et al. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID 37930669 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/neuropsychiatric-symptoms.md
• Lin FR, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023. PMID 37478886 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/risk-reduction-and-prevention.md
• Mintzer J, et al. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021. PMID 34570180 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/neuropsychiatric-symptoms.md
• Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015. PMID 25771249 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/risk-reduction-and-prevention.md
• Paczynski M, et al. Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol. 2025. PMID 40354064 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/notes/vandyck-2023-clarity-ad.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/red-flags-and-safety-concerns.md
• Qi L, et al. Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence. J Prev Alzheimers Dis. 2026. PMID 41478817 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Rabinovici GD, et al. Donanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2025. PMID 40155270 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/sims-2023-trailblazer-alz2.md, wiki/anti-amyloid-immunotherapy.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Rajji TK, et al. Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial. Nat Med. 2025. PMID 40133524 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/neuropsychiatric-symptoms.md
• Reuben DB, et al. Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers: The D-CARE Randomized Clinical Trial. JAMA. 2025. PMID 39878968 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, wiki/care-caregiving-and-health-systems.md, wiki/clinical-trials-landscape.md
• Salloway S, et al. TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease. Alzheimers Dement. 2025. PMID 40390253 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md
• Scheltens P, et al. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2026. PMID 41522368 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md
• Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023. PMID 37459141 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/sims-2023-trailblazer-alz2.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-trials-landscape.md, wiki/overview.md
• Sperling RA, et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023. PMID 37458272 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-trials-landscape.md
• van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023. PMID 36449413 — tags: [alzheimers-disease, anti-amyloid-trials] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/vandyck-2023-clarity-ad.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-trials-landscape.md, wiki/overview.md

Symptomatic therapy and neuropsychiatric symptoms

• Bahar-Fuchs A, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019. PMID 30909318 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Ballard C, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. PLoS Med. 2018. PMID 29408901 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/neuropsychiatric-symptoms.md
• Ballard C, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009. PMID 19138567 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/neuropsychiatric-symptoms.md, wiki/red-flags-and-safety-concerns.md
• Banerjee S, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011. PMID 21764118 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/neuropsychiatric-symptoms.md
• Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006. PMID 16437532 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Courtney C, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004. PMID 15220031 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Farlow MR, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther. 2010. PMID 20678673 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Gill SS, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009. PMID 19433698 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md, wiki/symptomatic-and-supportive-therapy.md
• Herring WJ, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020. PMID 31944580 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/neuropsychiatric-symptoms.md
• Howard R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012. PMID 22397651 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Howard R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015. PMID 26515660 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Lamb SE, et al. Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ. 2018. PMID 29769247 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• McShane R, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019. PMID 30891742 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/neuropsychiatric-symptoms.md, wiki/symptomatic-and-supportive-therapy.md
• Peters ME, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015. PMID 25585033 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: OPEN-QUESTIONS.md, wiki/neuropsychiatric-symptoms.md
• Porsteinsson AP, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014. PMID 24549548 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/neuropsychiatric-symptoms.md
• Schneider LS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006. PMID 17035647 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Schneider LS, et al. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005. PMID 16234500 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/neuropsychiatric-symptoms.md, wiki/red-flags-and-safety-concerns.md
• Steinberg M, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008. PMID 17607801 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Woods B, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2023. PMID 39804128 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Woods B, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018. PMID 29493789 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Birks JS, et al. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018. PMID 29923184 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Lim AWY, et al. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2024. PMID 39498781 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Birks JS, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015. PMID 25858345 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Tariot PN, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004. PMID 14734594 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• O'Regan J, et al. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015. PMID 26646039 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Graff MJ, et al. Effects of community occupational therapy on quality of life, mood, and health status in dementia patients and their caregivers: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2007. PMID 17895439 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• van der Steen JT, et al. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2025. PMID 40049590 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Soininen H, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017. PMID 29097166 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Soininen H, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimers Dement. 2021. PMID 32920957 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Katz IR, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999. PMID 10084637 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Mühlbauer V, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021. PMID 34918337 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/guidelines.md, wiki/neuropsychiatric-symptoms.md
• Reus VI, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry. 2016. PMID 27133416 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/guidelines.md, wiki/neuropsychiatric-symptoms.md
• Kales HC, et al. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015. PMID 25731881 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Tariot PN, et al. Trial of Pimavanserin in Dementia-Related Psychosis. N Engl J Med. 2021. PMID 34289275 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/clinical-trials-landscape.md, wiki/neuropsychiatric-symptoms.md
• Cummings JL, et al. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015. PMID 26393847 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/clinical-trials-landscape.md, wiki/neuropsychiatric-symptoms.md
• Herrmann N, et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. Am J Geriatr Psychiatry. 2019. PMID 31182351 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Husebo BS, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011. PMID 21765198 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Rosenberg PB, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010. PMID 20087081 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010. PMID 20220589 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• McCleery J, et al. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020. PMID 33189083 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md
• Xu J, et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015. PMID 25614508 — tags: [alzheimers-disease, symptomatic-neuropsychiatric] — cited by: wiki/neuropsychiatric-symptoms.md

Risk reduction and prevention

• Andrieu S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017. PMID 28359749 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: literature/statistics/STATISTICS.md, wiki/risk-reduction-and-prevention.md
• Eyting M, et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025. PMID 40175543 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: literature/statistics/STATISTICS.md, wiki/risk-reduction-and-prevention.md
• Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024. PMID 39096926 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: INDEX.md, wiki/risk-reduction-and-prevention.md
• Moll van Charante EP, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016. PMID 27474376 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/risk-reduction-and-prevention.md
• Stephan BCM, et al. Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2024. PMID 38824956 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/risk-reduction-and-prevention.md
• Barnes DE, et al. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011. PMID 21775213 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: wiki/risk-reduction-and-prevention.md
• Norton S, et al. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014. PMID 25030513 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: wiki/risk-reduction-and-prevention.md
• Kivipelto M, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001. PMID 11408299 — tags: [alzheimers-disease, risk-reduction-prevention] — cited by: wiki/risk-reduction-and-prevention.md

Care, caregiving and health systems

• Belle SH, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006. PMID 17116917 — tags: [alzheimers-disease, care-caregiving-systems] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/care-caregiving-and-health-systems.md, wiki/patient-experience-and-advocacy.md
• Callahan CM, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006. PMID 16684985 — tags: [alzheimers-disease, care-caregiving-systems] — cited by: wiki/care-caregiving-and-health-systems.md
• Kaddour L, et al. Anxiety in Informal Dementia Carers: A Meta-Analysis of Prevalence. J Geriatr Psychiatry Neurol. 2020. PMID 31409196 — tags: [alzheimers-disease, care-caregiving-systems] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/patient-experience-and-advocacy.md
• Pinquart M, et al. Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis. Psychol Aging. 2003. PMID 12825775 — tags: [alzheimers-disease, care-caregiving-systems] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/patient-experience-and-advocacy.md
• Walsh SC, et al. Palliative care interventions in advanced dementia. Cochrane Database Syst Rev. 2021. PMID 34582034 — tags: [alzheimers-disease, care-caregiving-systems] — cited by: wiki/care-caregiving-and-health-systems.md

Guidelines and regulatory documents

• Atri A, et al. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimers Dement. 2025. PMID 39713942 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Atri A, et al. The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments. Alzheimers Dement. 2025. PMID 39713939 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Brisson M, et al. CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimers Dement (N Y). 2020. PMID 33532543 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Chowdhary N, et al. Reducing the Risk of Cognitive Decline and Dementia: WHO Recommendations. Front Neurol. 2021. PMID 35082745 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Dickerson BC, et al. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care. Alzheimers Dement. 2025. PMID 39713957 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Filippi M, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012. PMID 22900895 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• García-Ribas G, et al. Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. Neurologia (Engl Ed). 2025. PMID 40685136 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Herrmann N, et al. CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimers Dement (N Y). 2022. PMID 35128025 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Hort J, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010. PMID 20831773 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Ismail Z, et al. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimers Dement. 2020. PMID 32725777 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Johnson KA, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013. PMID 23360977 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Martorana A, et al. Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection. Neurol Ther. 2025. PMID 39487946 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: wiki/guidelines.md
• Palmqvist S, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025. PMID 40729527 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/palmqvist-2024-blood-biomarkers-primary-care.md, literature/patient-voice/organizations.md, wiki/guidelines.md
• Petersen RC, et al. Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018. PMID 29282327 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Rabinovici GD, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med. 2025. PMID 39778970 — tags: [alzheimers-disease, guidelines-regulatory] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md

Safety, red flags and mimics

• AlDawsari A, et al. Use of sedative-hypnotic medications and risk of dementia: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022. PMID 34679196 — tags: [alzheimers-disease, safety-red-flags] — cited by: literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md
• Avelino-Silva TJ, et al. Association between delirium superimposed on dementia and mortality in hospitalized older adults: A prospective cohort study. PLoS Med. 2017. PMID 28350792 — tags: [alzheimers-disease, safety-red-flags] — cited by: literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md
• Bayliss EA, et al. High-Risk Medications in Persons Living With Dementia: A Randomized Clinical Trial. JAMA Intern Med. 2024. PMID 39432286 — tags: [alzheimers-disease, safety-red-flags] — cited by: wiki/red-flags-and-safety-concerns.md
• Boekholt M, et al. Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de. Age Ageing. 2025. PMID 40817636 — tags: [alzheimers-disease, safety-red-flags] — cited by: wiki/red-flags-and-safety-concerns.md
• Coupland CAC, et al. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019. PMID 31233095 — tags: [alzheimers-disease, safety-red-flags] — cited by: literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md
• DeKosky ST, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008. PMID 19017911 — tags: [alzheimers-disease, safety-red-flags] — cited by: literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md
• Dysken MW, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014. PMID 24381967 — tags: [alzheimers-disease, safety-red-flags] — cited by: wiki/red-flags-and-safety-concerns.md, wiki/symptomatic-and-supportive-therapy.md
• Sano M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997. PMID 9110909 — tags: [alzheimers-disease, symptomatic-therapy] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Dangpiaei S, et al. Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: a real-world evidence study. J Manag Care Spec Pharm. 2026. PMID 41885326 — tags: [alzheimers-disease, anti-amyloid, safety-red-flags] — cited by: wiki/symptomatic-and-supportive-therapy.md
• Fraade-Blanar LA, et al. Cognitive Decline and Older Driver Crash Risk. J Am Geriatr Soc. 2018. PMID 29667168 — tags: [alzheimers-disease, safety-red-flags] — cited by: wiki/red-flags-and-safety-concerns.md
• Geschwind MD, et al. Rapidly progressive dementia. Neurol Clin. 2007. PMID 17659190 — tags: [alzheimers-disease, safety-red-flags] — cited by: wiki/red-flags-and-safety-concerns.md
• Günak MM, et al. Risk of Suicide Attempt in Patients With Recent Diagnosis of Mild Cognitive Impairment or Dementia. JAMA Psychiatry. 2021. PMID 33760039 — tags: [alzheimers-disease, safety-red-flags] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md
• Schmutte T, et al. Suicide risk in first year after dementia diagnosis in older adults. Alzheimers Dement. 2022. PMID 34036738 — tags: [alzheimers-disease, safety-red-flags] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md
• van Steenhoven RW, et al. Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study. Neurology. 2026. PMID 42139653 — tags: [alzheimers-disease, safety-red-flags] — cited by: wiki/red-flags-and-safety-concerns.md

Patient experience and advocacy

• Abaasa A, et al. A qualitative investigation of the psychosocial services utilised by care-givers of patients with Alzheimer's disease and related dementias in southwestern Uganda. Ageing Soc. 2023. PMID 37680685 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Ainamani HE, et al. Caring for people with dementia in rural Uganda: qualitative study of caregiving burden experienced by informal and formal caregivers. J Glob Health Rep. 2020. PMID 33043153 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Bunn F, et al. Psychosocial factors that shape patient and carer experiences of dementia diagnosis and treatment: a systematic review of qualitative studies. PLoS Med. 2012. PMID 23118618 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Chejor P, et al. Experiences of older immigrants living with dementia and their carers: a systematic review and meta-synthesis. BMJ Open. 2022. PMID 35613772 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Goodson M, et al. A Qualitative Study on Formal and Informal Carers' Perceptions of Dementia Care Provision and Management in Malaysia. Front Public Health. 2021. PMID 34368037 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Kay J, et al. The experiences of living with dementia within an under-served geographical area: a systematic review and qualitative synthesis. Age Ageing. 2026. PMID 42341205 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/sources.md, wiki/patient-experience-and-advocacy.md
• Low LF, et al. Do people with early stage dementia experience Prescribed Disengagement®? A systematic review of qualitative studies. Int Psychogeriatr. 2018. PMID 28828999 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/README.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Lowe F, et al. The Experience of Stigma Within the Young Onset Dementia (YOD) Population: A Systematic Review of Qualitative Research. Health Expect. 2026. PMID 42478735 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/README.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Mukadam N, et al. A systematic review of ethnicity and pathways to care in dementia. Int J Geriatr Psychiatry. 2011. PMID 21157846 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Nguyen TA, et al. Experiences and perceptions of dementia in Vietnam and among the Vietnamese diaspora: a systematic review of qualitative studies. Aging Ment Health. 2023. PMID 35549573 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• O'Malley M, et al. Receiving a diagnosis of young onset dementia: a scoping review of lived experiences. Aging Ment Health. 2021. PMID 31647324 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Ramos C, et al. Understanding illness awareness in Alzheimer's disease: a qualitative study with patient-caregiver dyads in Colombia. Front Aging Neurosci. 2026. PMID 41717228 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Sadeghi-Mahalli N, et al. Factors affecting support: experiences of Iranian older spousal caregivers of people with Alzheimer's disease and their support resources. Aging Ment Health. 2025. PMID 39097934 — tags: [alzheimers-disease, patient-experience] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Scott TL, et al. A qualitative study exploring the experiences and needs of people living with young onset dementia related to driving cessation: 'It's like you get your legs cut off'. Age Ageing. 2023. PMID 37481262 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Sellars M, et al. Perspectives of people with dementia and carers on advance care planning and end-of-life care: A systematic review and thematic synthesis of qualitative studies. Palliat Med. 2019. PMID 30404576 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/README.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Tang X, et al. Lived experiences of maintaining self-identity among persons living with young-onset dementia: A qualitative meta-synthesis. Dementia (London). 2023. PMID 37646673 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/README.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• van der Lee J, et al. Factors related to sense of competence in family caregivers of people living with dementia in the community: a narrative synthesis. Int Psychogeriatr. 2019. PMID 30466499 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md
• Yu DSF, et al. Unravelling positive aspects of caregiving in dementia: an integrative review of research literature. Int J Nurs Stud. 2018. PMID 29128685 — tags: [alzheimers-disease, patient-experience] — cited by: literature/patient-voice/themes.md, wiki/patient-experience-and-advocacy.md

Cross-cutting and overview

• Bolt SR, et al. The perspectives of people with dementia on their future, end of life and on being cared for by others: A qualitative study. J Clin Nurs. 2022. PMID 33432696 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md
• Johnson KA, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013. PMID 23809369 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/guidelines/REGISTRY.md
• Johnson KA, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013. PMID 23753186 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/guidelines/REGISTRY.md
• Nygaard A, et al. What matters to you when the nursing is your home: a qualitative study on the views of residents with dementia living in nursing homes. BMC Geriatr. 2020. PMID 32600264 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md
• Smith EE, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. Alzheimers Dement (N Y). 2020. PMID 33209971 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/guidelines/REGISTRY.md
• Steeman E, et al. Living with early-stage dementia: a review of qualitative studies. J Adv Nurs. 2006. PMID 16796664 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md
• Yu J, et al. Dyadic coping experience of persons with young-onset dementia and their spousal caregivers: A review of qualitative studies and meta-synthesis. J Alzheimers Dis. 2025. PMID 40534425 — tags: [alzheimers-disease, cross-cutting] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md

Evidence-breadth additions — 2026-09-03

These records were added in the page-by-page substance pass and are grouped here as session provenance; their tags and cited-by fields identify their substantive destinations.

• Lafont S, et al. Driving cessation and self-reported car crashes in older drivers: the impact of cognitive impairment and dementia. J Geriatr Psychiatry Neurol. 2008;21:171-82. PMID 18503033. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/red-flags-and-safety-concerns.md
• Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-42. PMID 18568035. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/amyloid-biology.md
• Wilkosz PA, et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr. 2010;22:281-90. PMID 19781112. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/clinical-presentation-and-staging.md
• Potter R, et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra77. PMID 23761040. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/amyloid-biology.md, wiki/overview.md
• Mitsis EM, et al. A consecutive case series experience with florbetapir PET imaging in an urban dementia center. Mol Neurodegener. 2014;9:10. PMID 24484858. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/imaging-and-neuropathology.md, wiki/patient-experience-and-advocacy.md
• Schaller S, et al. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry. 2015;30:111-29. PMID 25320002. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Schmidt R, et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015;22:889-98. PMID 25808982. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/symptomatic-and-supportive-therapy.md
• Kosuge R, et al. Predictors of driving outcomes including both crash involvement and driving cessation in a prospective study of Japanese older drivers. Accid Anal Prev. 2017;106:131-140. PMID 28605692. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/red-flags-and-safety-concerns.md
• Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017;49:1373-1384. PMID 28714976. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/genetics.md
• Thyrian JR, et al. Effectiveness and safety of dementia care management in primary care: a randomized clinical trial. JAMA Psychiatry. 2017;74:996-1004. PMID 28746708. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/care-caregiving-and-health-systems.md
• Kishi T, et al. Memantine for Alzheimer's disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2017;60:401-425. PMID 28922160. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/symptomatic-and-supportive-therapy.md
• Noble JM, et al. Secular trends in the incidence of dementia in a multi-ethnic community. J Alzheimers Dis. 2017;60:1065-1075. PMID 28984588. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/epidemiology-and-burden.md
• Miners JS, et al. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimers Res Ther. 2019;11:81. PMID 31521199. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, wiki/vascular-and-metabolic-contributions.md
• Possin KL, et al. Effect of collaborative dementia care via telephone and internet on quality of life, caregiver well-being, and health care use. JAMA Intern Med. 2019;179:1658-1667. PMID 31566651. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/overview.md
• Grossberg GT, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week randomized trials. Am J Geriatr Psychiatry. 2020;28:383-400. PMID 31708380. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/neuropsychiatric-symptoms.md
• Choi JW, et al. Suicide risk within 1 year of dementia diagnosis in older adults: a nationwide retrospective cohort study. J Psychiatry Neurosci. 2021;46:E119-E127. PMID 33119492. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md
• Yu F, et al. Cognitive effects of aerobic exercise in Alzheimer's disease: a pilot randomized controlled trial. J Alzheimers Dis. 2021;80:233-244. PMID 33523004. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/symptomatic-and-supportive-therapy.md
• Pereira JB, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain. 2021;144:3505-3516. PMID 34259835. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/neuroinflammation-and-glia.md
• Cafferata RMT, et al. Effectiveness of cognitive stimulation for dementia: a systematic review and meta-analysis. Psychol Bull. 2021;147:455-476. PMID 34292011. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/symptomatic-and-supportive-therapy.md
• Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359-363. PMID 34588692. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/tau-biology-and-spread.md
• López-Ortiz S, et al. Exercise interventions in Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Ageing Res Rev. 2021;72:101479. PMID 34601135. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/symptomatic-and-supportive-therapy.md
• Janelidze S, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain. 2023;146:1592-1601. PMID 36087307. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md, wiki/overview.md
• Growdon ME, et al. New psychotropic medication use among Medicare beneficiaries with dementia after hospital discharge. J Am Geriatr Soc. 2023;71:1134-1144. PMID 36514208. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/red-flags-and-safety-concerns.md
• Wiggins M, et al. Young-onset dementia: a systematic review of the psychological and social impact on relatives. Patient Educ Couns. 2023;107:107585. PMID 36516659. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/patient-experience-and-advocacy.md
• Chatterjee P, et al. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum. Alzheimers Dement. 2023;19:1117-1134. PMID 36574591. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/fluid-biomarkers.md
• Lucey BP, et al. Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS. Ann Neurol. 2023;94:27-40. PMID 36897120. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/neuropsychiatric-symptoms.md
• Lv X, et al. Changes in CSF sPDGFRβ level and their association with blood-brain barrier breakdown in Alzheimer's disease with or without small cerebrovascular lesions. Alzheimers Res Ther. 2023;15:51. PMID 36915135. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, wiki/vascular-and-metabolic-contributions.md
• Zhou J, et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci Transl Med. 2023;15:eadf0141. PMID 36989373. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/neuroinflammation-and-glia.md
• Dejanovic B, et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models. Nat Aging. 2022;2:837-850. PMID 37118504. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/neuroinflammation-and-glia.md
• Lai M, et al. Journey to diagnosis of young-onset dementia: a qualitative study of people with young-onset dementia and their family caregivers in Australia. Dementia (London). 2023;22:1097-1114. PMID 37126513. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/patient-experience-and-advocacy.md
• Delrieu J, et al. Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial. Alzheimers Res Ther. 2023;15:183. PMID 37872582. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/risk-reduction-and-prevention.md
• Tay LX, et al. Economic burden of Alzheimer's disease: a systematic review. Value Health Reg Issues. 2024;40:1-12. PMID 37972428. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/care-caregiving-and-health-systems.md, wiki/epidemiology-and-burden.md
• Van Hulle C, et al. Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer's disease. Transl Psychiatry. 2024;14:3. PMID 38182581. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/vascular-and-metabolic-contributions.md
• Coley N, et al. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects. Lancet Healthy Longev. 2024;5:e120-e130. PMID 38310892. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/risk-reduction-and-prevention.md
• Vaishnav N, et al. Creating an unprotected class: addressing legal risks in the era of biologically-defined Alzheimer's disease. J Alzheimers Dis. 2024;98:187-195. PMID 38393896. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, wiki/diagnostic-criteria-and-biological-definition.md
• Honig LS, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. Alzheimers Res Ther. 2024;16:105. PMID 38730496. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/anti-amyloid-immunotherapy.md
• Ornish D, et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease. Alzheimers Res Ther. 2024;16:122. PMID 38849944. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/overview.md, wiki/risk-reduction-and-prevention.md
• Groot C, et al. Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment. JAMA Neurol. 2024;81:845-856. PMID 38857029. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/imaging-and-neuropathology.md
• Nakamura Y, et al. Brexpiprazole treatment for agitation in Alzheimer's dementia: a randomized study. Alzheimers Dement. 2024;20:8002-8011. PMID 39369280. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/neuropsychiatric-symptoms.md
• Schindler SE, et al. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology. Alzheimers Dement. 2024;20:8074-8096. PMID 39394841. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/fluid-biomarkers.md
• Sin MK, et al. Cerebral amyloid angiopathy, dementia, and Alzheimer neuropathologic changes: findings from the ACT autopsy cohort. Neurology. 2024;103:e210009. PMID 39481068. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/vascular-and-metabolic-contributions.md
• Ziontz J, et al. Connectivity, pathology, and ApoE4 interactions predict longitudinal tau spatial progression and memory. Hum Brain Mapp. 2024;45:e70083. PMID 39651679. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/tau-biology-and-spread.md
• Pilotto A, et al. Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain. 2025;148:408-415. PMID 39679606. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md
• Wolk DA, et al. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement. 2025;21:e14202. PMID 39807681. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, wiki/clinical-presentation-and-staging.md
• Roemer-Cassiano SN, et al. Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease. Sci Transl Med. 2025;17:eadp2564. PMID 39841807. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/tau-biology-and-spread.md
• Kim Y, et al. Clinical practice guidelines for dementia: recommendations for cholinesterase inhibitors and memantine. Dement Neurocogn Disord. 2025;24:1-23. PMID 39944527. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Byeon G, et al. Clinical practice guidelines for dementia: recommendations for the pharmacological treatment of behavioral and psychological symptoms. Dement Neurocogn Disord. 2025;24:24-43. PMID 39944528. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Kwok JYY, et al. Multicomponent intervention for distressed informal caregivers of people with dementia: a randomized clinical trial. JAMA Netw Open. 2025;8:e250069. PMID 40094667. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, wiki/care-caregiving-and-health-systems.md
• Bateman RJ, et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the DIAN-TU trial. Lancet Neurol. 2025;24:316-330. PMID 40120616. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/clinical-trials-landscape.md
• Yin XS, et al. Prevalence of cerebral amyloid angiopathy and its correlation with Alzheimer's disease and cognition in an autopsy-confirmed cohort from China. Alzheimers Dement (Amst). 2025;17:e70100. PMID 40201593. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/vascular-and-metabolic-contributions.md
• Baker LD, et al. Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: the EXERT study. Alzheimers Dement. 2025;21:e14586. PMID 40271888. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/overview.md, wiki/risk-reduction-and-prevention.md
• Windon CC, et al. Amyloid PET and clinical management in a diverse, cognitively impaired population: the New IDEAS Study. Alzheimers Dement. 2025;21:e70504. PMID 40728069. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/diagnostic-criteria-and-biological-definition.md, wiki/imaging-and-neuropathology.md, wiki/overview.md
• Radmard M, et al. Functional imaging in Alzheimer's disease: a systematic review and meta-analysis of ASL-MRI and FDG-PET. J Neuroimaging. 2025;35:e70080. PMID 40898829. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/imaging-and-neuropathology.md
• Wang B, et al. Comparative diagnostic accuracy of AI-assisted fluorine-18 fluorodeoxyglucose positron emission tomography versus structural magnetic resonance imaging in Alzheimer disease. JMIR Aging. 2025;8:e76981. PMID 41061249. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/imaging-and-neuropathology.md
• Pahlke S, et al. Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis. Alzheimers Dement. 2025;21:e70828. PMID 41193403. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: OPEN-QUESTIONS.md, literature/BIBLIOGRAPHY.md, literature/statistics/STATISTICS.md, wiki/fluid-biomarkers.md, wiki/guidelines.md
• van Dyck CH, et al. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the CLARITY AD open-label extension study. Alzheimers Dement. 2025;21:e70905. PMID 41355080. — tags: [alzheimers-disease, 2026-09-03-deepening] — cited by: literature/BIBLIOGRAPHY.md, wiki/anti-amyloid-immunotherapy.md, wiki/clinical-trials-landscape.md

Added by the 2026-09-03 audit

• Parks AL, et al. A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment. J Alzheimers Dis. 2025;105:494-504. PMID 40207637. — tags: [patient-experience, anti-amyloid, qualitative] — cited by: OPEN-QUESTIONS.md, wiki/patient-experience-and-advocacy.md
• Katayama S, et al. Care partners' perceptions of amyloid-targeting therapy and treat-to-clearance for Alzheimer's disease in Japan: a qualitative study. Neurol Ther. 2026;15:257-267. PMID 41307609. — tags: [patient-experience, anti-amyloid, care-partners, qualitative] — cited by: OPEN-QUESTIONS.md, wiki/patient-experience-and-advocacy.md